Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
06/2012
06/07/2012US20120142726 Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
06/07/2012US20120142716 4-pyrimidinesulfamide derivative
06/07/2012US20120142692 Antifolate combinations
06/07/2012US20120142680 Heteroalkyl linked pyrimidine derivatives
06/07/2012US20120142677 Pyrrolidine Compounds Which Modulate The CB2 Receptor
06/07/2012US20120142675 Methods for Treating Diseases of the Retina
06/07/2012US20120142670 N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy
06/07/2012US20120142669 N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy
06/07/2012US20120142666 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor
06/07/2012US20120142664 Novel benzyl azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142663 Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142662 Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142661 Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142652 Compositions and methods for localized therapy of the eye
06/07/2012US20120142642 Novel oxime derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142640 Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators
06/07/2012US20120142639 Oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012US20120142638 Combination of organic compounds
06/07/2012US20120142630 Process for purifying guar
06/07/2012US20120142620 Core 2 glcnac-t inhibitors
06/07/2012US20120142609 Non human animal models for increased retinal vascular permeability
06/07/2012US20120142608 Rca locus analysis to assess susceptibility to amd and mpgnii
06/07/2012US20120142596 Agent for stimulating mobilization of endothelial progenitor cells
06/07/2012US20120142591 Method of treating intraoccular tissue pathologies with nerve growth factor
06/07/2012US20120142589 Tissue-protective cytokines for the protection, restoration and enhancement of responsive cells, tissues and organs
06/07/2012US20120141573 Cell Lines That Secrete Anti-Angiogenic Antibody-Scaffolds and Soluble Receptors and Uses Thereof
06/07/2012US20120141564 Compositions and methods of treating inflammation
06/07/2012US20120141532 Botulinum Toxin Formulation
06/07/2012US20120141500 Antibodies Against Human Angiopoietin 2
06/07/2012US20120141490 Antibodies That Bind Selectively To P25 And Uses Therefor
06/07/2012US20120141457 Lateral Flow Immunoassay for Complement Activation and Methods of Use for Point-of-Care Assessment of Complement-Associated Disorders
06/07/2012US20120141449 Albumin Fusion Proteins
06/07/2012US20120141447 Nutritional supplement
06/07/2012US20120141443 Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
06/07/2012US20120141422 Widespread gene delivery to the retina using systemic administration of aav vectors
06/07/2012US20120141415 Albumin Fusion Proteins
06/07/2012US20120141410 Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca
06/07/2012US20120141408 High Water Content Ophthalmic Devices
06/07/2012US20120141401 Soft anticholinergic zwitterions
06/07/2012US20120141379 Microspheres for active embolization
06/07/2012US20120138506 Methods of treatment and pharmaceutical composition
06/07/2012CA2819624A1 Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators
06/07/2012CA2819619A1 Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012CA2819616A1 Methods for treating diseases of the retina
06/07/2012CA2819457A1 Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
06/07/2012CA2815374A1 Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
06/06/2012EP2460801A1 Bicyclic compound and use thereof for medical purposes
06/06/2012EP2459593A2 Anti-tgf-beta receptor type ii single domain antibodies
06/06/2012EP2459589A1 Mutants pf4 polypeptides exhibiting an increased anti-angiogenic activity
06/06/2012EP2459581A2 Liver x receptor agonists
06/06/2012EP2459572A2 Spirocyclic amide derivatives
06/06/2012EP2459542A1 Selective alpha 2b/2c agonists
06/06/2012EP2459195A1 Compositions and methods for inhibition of the jak pathway
06/06/2012EP2459186A1 Ophthalmic solution for protecting internal structures of the eyeball against uv-a rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique
06/06/2012CN1535149B Topical application of thiazolyl amides
06/06/2012CN102028889B Chinese medicinal preparation for treating myopia
06/06/2012CN101920019B Hydrophilic polymer-puerarin specific conjugated non-hemolytic conjugate
06/06/2012CN101638404B High-purity salvianolic acid B and preparation method and application thereof
06/06/2012CN101511369B Methods and compositions for inhibiting angiogenesis.
06/06/2012CN101213187B Isoquinoline derivatives as inhibitors of RHO-kinase
06/06/2012CN101151034B Meninges nerve cell protector containing prostaglandin F2alpha derivative as effective component
06/05/2012US8193231 Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof
06/05/2012US8193230 Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof
06/05/2012US8193229 Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors
06/05/2012US8193166 Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation
06/05/2012US8192732 Mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
06/05/2012CA2406278C Inhibitors of human phosphatidyl-inositol 3-kinase delta
06/05/2012CA2368670C Modulation of vascular permeability by means of tie2 receptor activators
05/2012
05/31/2012WO2012071184A1 Indole derivatives as modulators of s1p receptors
05/31/2012WO2012070649A1 Highly-soluble pyrroloquinoline quinone salt and method for producing same
05/31/2012WO2012069221A1 Therapeutical method for the treatment of the leber optic
05/31/2012WO2012068612A1 Methods of treating eye diseases associated with inflammation and vascular proliferation
05/31/2012WO2012033789A3 Treatment of diseases
05/31/2012WO2012033348A3 Composition for the prevention or treatment of allergic diseases comprising 2-linoleoyl glycerol
05/31/2012WO2011161295A3 Use of anticalcineurin compounds for the treatment of pathologies involving ocular neovascularisation
05/31/2012US20120136052 Substituted acylanilides and methods of use thereof
05/31/2012US20120136048 Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
05/31/2012US20120136044 Compositions And Methods Of Inhibiting NADPH Oxidase Expression
05/31/2012US20120136041 Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists
05/31/2012US20120136037 Deuterium-enriched ruboxistaurin
05/31/2012US20120136036 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
05/31/2012US20120136026 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof
05/31/2012US20120136013 Organic compounds
05/31/2012US20120135994 Inhibitors of human phosphatidylinositol 3-kinase delta
05/31/2012US20120135992 Cyclic triazo sodium channel blockers
05/31/2012US20120135984 Dual-action inhbitors and methods of using same
05/31/2012US20120135964 Certain chemical entities, compositions, and methods
05/31/2012US20120135959 Metalloprotein inhibitors containing nitrogen based ligands
05/31/2012US20120135958 Tetrahydroquinoxaline urea derivatives, preparation thereof, and therapeutic use thereof
05/31/2012US20120135947 Oil-in-water emulsion composition containing difluprednate and tobramycin
05/31/2012US20120135939 Cyclosporin Analogs
05/31/2012US20120135084 Use of Deuterium Oxide for Treating Viral Diseases of the Eye
05/31/2012US20120135066 Regulators of the hedgehog pathway, compositions and uses related thereto
05/31/2012US20120135022 Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essentially consisting of vp3
05/31/2012US20120135016 Induction of neurogenesis and stem cell therapy in combination with copolymer 1
05/31/2012US20120135000 Methods and compositions for treating ocular disorders
05/31/2012US20120134982 Polypeptides, antibody variable domains & antagonists
05/31/2012CA2815390A1 Methods of treating eye diseases associated with inflammation and vascular proliferation
05/30/2012EP2456451A1 Inhibitor of inflammatory conditions
05/30/2012EP2456429A1 Composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
1 ... 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 ... 531